The Rise of Non-Steroidal MRAs (Finerenone)
In 2026, Finerenone (a non-steroidal MRA) has gained significant traction in the UK market. While traditional MRAs like spironolactone are effective, they often cause side effects like high potassium (hyperkalaemia).
Finerenone offers a more selective approach, particularly for patients who also have Chronic Kidney Disease (CKD) and Type 2 Diabetes. It effectively reduces the progression of heart failure with a lower risk of the hormonal side effects seen with older steroidal MRAs.
1 View
